SPC Financial Inc. grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,375 shares of the biopharmaceutical company’s stock after purchasing an additional 300 shares during the quarter. SPC Financial Inc.’s holdings in Bristol-Myers Squibb were worth $289,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Financial Gravity Wealth Inc. bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $26,000. Private Ocean LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $28,000. Trust Department MB Financial Bank N A bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at approximately $32,000. James Investment Research Inc. grew its holdings in shares of Bristol-Myers Squibb by 36.5% during the first quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 219 shares during the last quarter. Finally, Endurance Wealth Management Inc. grew its holdings in shares of Bristol-Myers Squibb by 119.6% during the second quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 500 shares during the last quarter. 77.37% of the stock is owned by institutional investors.
In other news, Director Robert J. Bertolini purchased 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was purchased at an average cost of $44.72 per share, with a total value of $491,920.00. Following the purchase, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.
A number of brokerages recently issued reports on BMY. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Wednesday. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 2nd. UBS Group decreased their price objective on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a report on Thursday, June 13th. JPMorgan Chase & Co. began coverage on Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 price objective for the company. Finally, Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $55.88.
NYSE BMY traded up $0.11 on Thursday, reaching $45.75. 541,593 shares of the stock traded hands, compared to its average volume of 15,150,168. The stock’s fifty day moving average price is $45.29. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. The company has a market capitalization of $76.06 billion, a P/E ratio of 11.47, a price-to-earnings-growth ratio of 2.30 and a beta of 0.73. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The firm had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company posted $1.01 EPS. Research analysts predict that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Percentage Decliners
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.